The adenosine A2A receptor has emerged as an attractive non-dopaminergic target in the pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS distribution. It is highly enriched in striatopallidal neurons and can form functional heteromeric complexes with other G-protein-coupled receptors, including dopamine D2, metabotropic glutamate mGlu5 and adenosine A1 receptors. Blockade of the adenosine A2A receptor in striatopallidal neurons reduces postsynaptic effects of dopamine depletion, and in turn lessens the motor deficits of PD. A2A antagonists might partially improve not only the symptoms of PD but also its course, by slowing the underlying neurodegeneration and reducing the maladaptive neuroplasticity that complicates standard ‘dopamine replacement’ treatments. Thus, we review here a prime example of translational neuroscience, through which antagonism of A2A receptors has now entered the arena of clinical trials with realistic prospects for advancing PD therapeutics.

Targeting adenosine A2A receptors in Parkinson's disease / M. A., Schwarzschild; Agnati, Luigi Francesco; K., Fuxe; J., Chen; M., Morelli. - In: TRENDS IN NEUROSCIENCES. - ISSN 0166-2236. - STAMPA. - 29:(2006), pp. 647-654.

Targeting adenosine A2A receptors in Parkinson's disease.

AGNATI, Luigi Francesco;
2006-01-01

Abstract

The adenosine A2A receptor has emerged as an attractive non-dopaminergic target in the pursuit of improved therapy for Parkinson's disease (PD), based in part on its unique CNS distribution. It is highly enriched in striatopallidal neurons and can form functional heteromeric complexes with other G-protein-coupled receptors, including dopamine D2, metabotropic glutamate mGlu5 and adenosine A1 receptors. Blockade of the adenosine A2A receptor in striatopallidal neurons reduces postsynaptic effects of dopamine depletion, and in turn lessens the motor deficits of PD. A2A antagonists might partially improve not only the symptoms of PD but also its course, by slowing the underlying neurodegeneration and reducing the maladaptive neuroplasticity that complicates standard ‘dopamine replacement’ treatments. Thus, we review here a prime example of translational neuroscience, through which antagonism of A2A receptors has now entered the arena of clinical trials with realistic prospects for advancing PD therapeutics.
29
647
654
Targeting adenosine A2A receptors in Parkinson's disease / M. A., Schwarzschild; Agnati, Luigi Francesco; K., Fuxe; J., Chen; M., Morelli. - In: TRENDS IN NEUROSCIENCES. - ISSN 0166-2236. - STAMPA. - 29:(2006), pp. 647-654.
M. A., Schwarzschild; Agnati, Luigi Francesco; K., Fuxe; J., Chen; M., Morelli
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/593428
Citazioni
  • ???jsp.display-item.citation.pmc??? 131
  • Scopus 383
  • ???jsp.display-item.citation.isi??? 351
social impact